BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jun 16, 2008
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 6/13 cls
Amylin (NASDAQ:AMLN) Jefferies Salveen Kochnover Downgrade Hold (from buy) -10% $27.03
Kochnover lowered her target to $33 from $47 after Novo Nordisk (NYSE:NVO) presented data comparing its liraglutide to Amylin's Byetta. She believes less frequent dosing and clinical superiority could make liraglutide a formidable competitor (see "Cover Story").
Applied Biosystems (NYSE:ABI) UBS Derik De Bruin Downgrade Neutral (from buy) 0% $33.53
De Bruin raised his target to $38 from $37 to reflect the $38 price per share that Invitrogen (NASDAQ:IVGN) is offering to acquire ABI (see "Invitrogen Needs Uplift," A17).
Bradmer (TSX:BMR) Dundee David Martin New Neutral -8% C$1.10
Martin believes there is a 60-65% chance the company's Neuradiab will provide...

Read the full 926 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >